Meet Our Editorial Board Member

Current Pharmaceutical Biotechnology, 2015, Vol. 16, No. 10 851

Meet Our Editorial Board Member

S. Moein Moghimi
Nanomedicine Laboratory, Centre for Pharmaceutical Nanotechnology and Nanotoxicology
Department of Pharmacy, University of Copenhagen, Universitetsparken 2
DK-2100 Copenhagen , Denmark
Moein Moghimi is a graduate of the University of Manchester and Charing Cross and Westminster
Medical School (Imperial College, London). He joined the University of Copenhagen in 2008 where he
serves as the Professor of Nanomedicine at the Department of Pharmacy, Professor of Pharmaceutical
Nanotechnology at the NanoScience Centre, and Director of the Centre for Pharmaceutical Nanotechnology and Nanotoxicology. He is also a Full Affiliate Member at the Department of Translational Imaging, Houston Methodist Research Institute, Texas, USA; Adjoint Professor of Nanomedicine at the
Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences,
University of Colorado-Denver Medical Center (USA), and a Visiting Professor at Universit Degli
Studi Di Padua (Italy). Between 2008 and 2010, he served as the Honorary Professor of Nanomedicine
at the Multidisciplinary Research Center, Shantou University (China).
Professor Moghimis research concentrates on nanotherapeutics and nanosafety, where he has published and cited extensively, and has been the recipient of numerous research achievement awards. Nanotherapeutics encompasses technologies and
system approaches that achieve and facilitate earlier and more precise individual diagnosis, improved targeted therapies (eliminating side effects) and enhanced therapeutic monitoring [1]. On a broader context, these approaches are enabling tools for personalized and targeted medicine that can deal with the grand challenges of chronic diseases in an aging population. Currently,
his work is addressing: (a) translational aspects of nanocarrier design and nanotherapeutic engineering (Safe-by-Design and
Simple-by-Design concepts) and their performance assessment through systems approaches, (b) validation of animal models
of human diseases for nanopharmaceutical pharmacokinetics and therapeutic assessments, and (c) a long-term concomitant extensive computational network knowledge of genomics and epigenetics of inter-individual variations to nanopharmaceutical
performance and adverse immune responses [2-6]. Inflammation processes are the core targets for these engineered nanotherapeutics, and include cancer, neurological pathologies (e.g., Alzheimers disease), cardiovascular diseases (e.g., atherosclerosis),
skin conditions (e.g., psoriasis), and allergy. Along with the majority of chronic inflammatory diseases, unrelieved pain is a
major global health care problem, including acute pain after surgery and trauma, and chronic pain. The latter affects one in five
adults, impairs everyday activities, social functions, productivity, and quality of life, and carries great direct and indirect economic costs. Accordingly, Moghimis laboratory is further contributing to the development of innovative nanotechnologies that
addresss chronic pain with the aim of improving peoples condition suffering from debilitating diseases.
Professor Moghimis earlier research work and achievements have included precision design and surface engineering of
nanoparticles and functional nanosystems for parenteral site-specific targeting/drug delivery and imaging modalities (splenotropic entities, lymphotropic agents, phagocyte-resistant nanoparticles, cerebral endothelial cell specific nanoplatforms and
anti-cancer nanomedicine) as well as in understanding of complex mechanisms pertaining nanomaterial-mediated infusion reactions and integrated cell death processes [1, 7, 8]. This work eventually led to the development of advanced medium throughput
approaches and establishment of molecular protocols for rapid assessing of nanomaterial-induced bioenergetic crisis, cell death
mechanisms, and complement activation processes [9-16].
Professor Moghimi has spoken and lectured widely on nanomedicine and nanosafety at the invitation of many international
conferences and prestigious organizations to include the American Society for Gene & Cell Therapy, BioNanomed (Austria),
Cedars Sinai Medical Center, CLINAM (Switzerland), College de France, COST Action, Daniels College of Business (Colorado, USA), ESF-EMBO, European Material Research Society, Hoffmann La Roche, Institut Galien Paris-Sud (UMR-CNRS),
Controlled Release Society (Italian Chapter, Malaysian Chapter), Nanotechnology Characterization Laboratory and Frederick
National Laboratory for Cancer Research (USA), New York Academy of Sciences, Volkswagen Foundation (Germany), Sanfoi
Research and Development, Society for Brain Mapping and Therapeutics (USA), Stanford University, Tsinghua University,
University of California at Santa Barbara, and University of Vienna in the past few years.
Outside the university, Professor Moghimi practices in the capacity of consultant to numerous pharmaceutical, biotechnology, health and food industries as well as investment banks, management consultancy firms and other entrepreneurial enterprises world-wide. He is a regular assessor and expert evaluator in nanomedicine/nanosafety for governmental bodies and private organizations in more than 25 countries. In addition to his role as the Immunology Section Editor of Current Pharmaceutical Biotechnology, Professor Moghimi further serves as the Associate Editor of Nanomedicine: NBM (Elsevier) and the Journal
of Biomedical Nanotechnology (American Scientific Publishers), and features on the editorial boards of numerous high-impact
international journals to include Nanomedicine-UK (Future Medicine) and Advanced Drug Delivery Reviews (Elsevier).

852 Current Pharmaceutical Biotechnology, 2015, Vol. 16, No. 10

Meet Our Editorial Board Member

REFERENCES
[1]
[2]
[3]
[4]
[5]

[6]
[7]
[8]
[9]
[10]
[11]
[12]

[13]
[14]
[15]

[16]

Moghimi, S.M.; Hunter, A.C.; Murray, J.C. Nanomedicine: Current status and future prospects. FASEB J., 2005, 19, 311-330.
Moghimi, S.M.; Peer, D.; Langer R. Re-shaping the future of nanopharmaceuticals: ad iduicium. ACS Nano., 2011, 5, 8454-8458.
Moghimi, S.M.; Hunter, A.C.; Andresen, T.L. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu. Rev.
Pharmacol. Toxicol., 2012, 52, 481-503.
Moghimi, S.M.; Wibroe, P.P.; Helvig, S.; Farhangrazi, Z.S.; Hunter, A.C. Genomic perspectives in inter-individual adverse responses following
nanomedicine administration: the way forward. Adv. Drug Deliv. Rev., 2012, 64, 1385-1393.
Sharifzadeh, Z.; Rahbarizadeh, F.; Shokrgozar, M.A.; Ahmadvand, D.; Mahboudi, F.; Rahimi Jamnani, F.; Moghimi, S.M. Genetically engineered
cytotoxic T cells bearing nanoconstructed chimeric receptors harbouring TAG-72-specific camelid single domain antibodies as targeting agents. Cancer Lett., 2013, 334, 237-244.
Moghimi, S.M.; Farhangrazi, Z.S. Just so stories: Random acts of anti-cancer nanomedicine performance. Nanomed. Nanotechnol. Biol. Med., 2014,
10, 1661-1666.
Moghimi, S.M.; Hunter, A.C.; Murray, J.C. Long circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev., 2001, 53, 283-318.
Moghimi, S.M.; Symonds, P.; Murray, J.C.; Hunter, A.C.; Debska, G.; Szewczyk, A. A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene-transfer/therapy. Mol. Ther., 2005, 11, 990-995.
Hamad, I.; Al-Hanbali, O.; Hunter, A.C.; Rutt, K.J.; Andresen, T.L.; Moghimi, S.M. Distinct polymer architecture mediates switching of complement
activation pathways at nanosphere-serum interface: Implications for stealth nanoparticle engineering. ACS Nano., 2010, 4, 6629-6638.
Benjaminsen, R.V.; Mattebjerg, M.A.; Henriksen, J.R.; Moghimi, S.M.; Andresen, T.L. The possible proton-sponge effect of polyethylenimine does
not include change in lysosomal pH. Mol. Ther., 2013, 21, 147-157.
Moghimi, S.M. Cancer nanomedicines and the complement system activation paradigm: Anaphylaxis and tumour growth. J. Control Rel., 2014, 190,
556-562.
Banda, N.K.; Mehta, G.; Chao, Y.; Wang, G.; Inturi, S.; Fossati-Jimak, L.; Botto, M.; Wu, L-P.; Moghimi, S.M.; Simberg, D. Mechanisms of complement activation by superparamagentic dextran iron oxide (SPIO) nanoworms in mouse versus human sera. Particle Fibre Toxicol., 2014, 11, 64,
doi:10.1186/s12989-014-0064-2.
Wu, L-P.; Wang, D.; Parhamifar, L.; Hull, A.; Chen, G-Q.; Moghimi, S.M. Poly(3-hydroxybutyrate-co-R-3-hydroxyhexanoate) nanoparticles with
polyethylenimine coat as simple, safe and versatile vehicles for cell targeting: population characteristics, cell uptake and intracellular trafficking. Adv.
Healthcare Mat., 2014, 3, 817-824.
Parhamifar, L.; Andersen, H.; Wu, L-P.; Hall, A.; Hudzech, D.; Moghimi, S.M. Polycation-mediated integrated cell-death processes. Adv. Genetics,
2014, 88, 353-398.
Hall, A.; Parhamifar, L.; Krarup Lange, M.; Meyle, K.D.; Sanderhoff, M.; Roursgaard, M.; Larsen, A.K.; Andersen, H.; Jensen, P.B.; Bartek, J.;
Moghimi, S.M. Polyethylenimine architecture-dependent metabolic imprints and perturbation of cellular redox homeostasis. Biochim Biophys Acta Bioenergetics, 2015, 1847, 328-342.
Hall, A.; Wu, LP.; Parhamifar, L.; Moghimi, S.M. Differential modulation of cellular bioenergetics by poly(L-lysine)s of different molecular weights.
Biomacromolecules, 2015, 16, 2119-2126.